



Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

October 14, 2025

- A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had significantly lower healthcare costs than non-adherent patients
- Post-hoc analyses of a Phase 3 safety study showed that patients taking YUPELRI had significantly lower incidence of moderate-to-severe acute exacerbations, and overall, less severe exacerbations, than patients taking tiotropium

DUBLIN, Oct. 14, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced that it will be presenting two rapid-fire presentations at CHEST 2025, the annual meeting of the American College of Chest Physicians taking place from October 19-22, 2025, in Chicago, IL.

"We are pleased to share new analyses on YUPELRI at the upcoming CHEST Annual Meeting. The findings of the retrospective database analysis of claims data evaluating exacerbations in the 3 months following hospital discharge demonstrates that adherent patients to YUPELRI had significantly fewer exacerbations, and particularly less severe ones, compared to non-adherent patients," commented Antonio Anzueto, M.D., Professor of Medicine, Pulmonary/Critical Section, University of Texas, Health San Antonio. "The analysis not only showed that exacerbations were lower in adherent patients, but also their healthcare-related use and costs were significantly lower, highlighting the dual benefit of YUPELRI on patient outcomes. We are also presenting additional insights from the post-hoc analyses of the 52-week Phase 3 safety study highlighted that the YUPELRI exacerbation profile over 1 year is at least as effective as tiotropium. Taken together, the new analyses further strengthen the already compelling evidence for YUPELRI's use as a once-daily nebulized maintenance treatment for patients with COPD."

Details on the presentations are as follows:

Title: [Exacerbation Rates in COPD Patients: A Retrospective Analysis of the Nebulized Once Daily Long-Acting Muscarinic Antagonist Revefenacin in a 52-Week Safety Study](#)

Presenter: Edmund J Moran, Ph.D., Theravance Biopharma

Date and time: October 21, 2025; 10:56 – 11:00 AM CT; Emerging Trends in COPD

Title: [Adherence to Revefenacin Associated with Reductions in Exacerbations and Healthcare Costs Following a COPD-Related Hospitalization](#)

Presenter: Grace Leung, MPH, Zavicus Consulting

Date and time: October 21, 2025; 2:15 – 2:19 PM CT; Current Updates in COPD

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver *Medicines that Make a Difference*® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first-in-class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI® is a registered trademark of Viatrix Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

About Theravance Biopharma / Viatrix Collaboration

Theravance Biopharma and Viatrix Inc. and their respective affiliates have established a strategic collaboration to develop and commercialize nebulized revefenacin products for COPD.

Forward-Looking Statements


This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations and future events. Theravance Biopharma, Inc. (the "Company") intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: the Company's expectations regarding its future profitability, expenses and uses of cash, the Company's goals, designs, strategies, plans and objectives, future growth of YUPELRI sales, future royalty payments, the ability to provide value to shareholders, the Company's regulatory strategies and timing of clinical studies, possible safety, efficacy or differentiation of our investigational therapy, the status of patent infringement litigation initiated by the Company and its partner against certain generic companies in federal district courts, contingent payments due to

the Company from the sale of the Company's TRELEGY ELLIPTA royalty interests to Royalty Pharma, and expectations around the use of OHSAs as endpoints for clinical trials. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: factors that could increase the Company's cash requirements or expenses beyond its expectations and any factors that could adversely affect its profitability, whether the milestone thresholds can be achieved, delays or difficulties in commencing, enrolling or completing clinical studies, the potential that results from clinical or non-clinical studies indicate the Company's product candidates or product are unsafe, ineffective or not differentiated, risks of decisions from regulatory authorities that are unfavorable to the Company, dependence on third parties to conduct clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with or relying on third parties to discover, develop, manufacture and commercialize products, and risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate technical expertise and supporting infrastructure, the ability of the Company to protect and to enforce its intellectual property rights, volatility and fluctuations in the trading price and volume of the Company's shares, and general economic and market conditions. Other risks affecting the Company are in the Company's Form 10-Q filed with the SEC on August 13, 2025, and other periodic reports filed with the SEC. In addition to the risks described above and in Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma's results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

Contact:

investor.relations@theravance.com

650-808-4045

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-new-analyses-highlighting-yupelri-revefenacin-outcomes-in-copd-at-the-2025-chest-annual-meeting-302583065.html>

SOURCE Theravance Biopharma, Inc.